KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Other Non-Current Assets (2016 - 2026)

Biocryst Pharmaceuticals filings provide 15 years of Other Non-Current Assets readings, the most recent being $5.7 million for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets rose 9.99% to $5.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.7 million, a 9.99% increase, with the full-year FY2025 number at $5.7 million, up 9.99% from a year prior.
  • Other Non-Current Assets hit $5.7 million in Q4 2025 for Biocryst Pharmaceuticals, up from $4.4 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $13.0 million in Q1 2024 to a low of $80000.0 in Q4 2023.
  • Median Other Non-Current Assets over the past 5 years was $6.1 million (2021), compared with a mean of $6.2 million.
  • Biggest five-year swings in Other Non-Current Assets: plummeted 98.82% in 2023 and later skyrocketed 6346.25% in 2024.
  • Biocryst Pharmaceuticals' Other Non-Current Assets stood at $6.5 million in 2021, then grew by 5.16% to $6.8 million in 2022, then plummeted by 98.82% to $80000.0 in 2023, then surged by 6346.25% to $5.2 million in 2024, then rose by 9.99% to $5.7 million in 2025.
  • The last three reported values for Other Non-Current Assets were $5.7 million (Q4 2025), $4.4 million (Q3 2025), and $3.6 million (Q2 2025) per Business Quant data.